The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) focuses on advancing the science and understanding of CLL and lymphoproliferative disorders.
Long Beach
Joined May 2012
- Tweets355
- Following133
- Followers1.5K
- Likes110
iwCLL retweeted
CLL Society Chief Medical Officer @briankoffman presented results from @CLLAdvocates study Global Perspective on CLL Management-Real World Data and Patient Experiences at #iwCLL2023. We're proud to be presenting this crucial research about the patient experience in #CLL! @iwcll
iwCLL retweeted
The calm before the storm in Boston @iwCLL #iwCLL2023, ready for the Young Investigator Meeting today!
iwCLL retweeted
The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) hosts its 20th biennial meeting in Boston Oct. 6-9. prn.to/48CYZp6
iwCLL retweeted
We will be attending #iwCLL2023 in Boston!
Join us on 6th – 9th October as we share the latest #CLL updates on VJHemOnc.com! Don't miss out.
@iwCLL #CLLsm #LeuSM #HemOnc
iwCLL retweeted
Submit your abstract to iwCLL. It’s a great conference to connect with peers working on #CLL
Have you submitted your abstract for #iwCLL2023?
This year's event is taking place October 6-9, 2023 in Boston, MA. Click here to submit your abstract: bit.ly/3LLcAS3
For additional program details & updates, visit IWCLL2023.ORG.
iwCLL retweeted
Although @iwCLL will be virtual, I am still looking forward to it. 2 of our fantastic students from @UNCPharmacy will be presenting posters at this international conference with great guidance & collaboration from @calliecoombsmd @KatieBPharmD @sarahstump1 and @anthonymatomd!
iwCLL retweeted
PS: If your abstract is accepted for oral or poster presentation at #iwCLL2021, your @iwCLL meeting registration will be COMPLIMENTARY. Just in case you needed another incentive to submit a #CLL abstract by 30 June 2021. Visit iwcll2021.org/abstracts/ for full guidelines.
iwCLL retweeted
Exciting #ASCO21 Update: Dr. Richard Furman explains results from a phase 3 #clinicaltrial comparing two different treatment options for patients with chronic lymphocytic leukemia (#CLL) bit.ly/3z5S7i6 #leusm #lymsm
iwCLL retweeted
Are you up to date on the latest evidence on BTK inhibitors for #CLL? Find out from the experts in this live CME/MOC/NCPD/CPE-accredited web broadcast on June 9 at 6:30 PM EDT #ASCO21 #MedEd bit.ly/CLL21Live
iwCLL retweeted
The YIM is always one of my favorite parts of the iwCLL meeting @Othman_Al_Sawaf @anthonymatomd @LRoekerMD @jeff_sharman @inhyeahn @MrazLab @NitinJainMD @DanilovLab
#iwCLL2021 is preceded by our YIM, which offers an opportunity for participants to present & discuss their data with peers, and seeks to encourage emerging talent devoted to making an impact in the care of patients with hematological malignancies. More at bit.ly/3rc7C3x!
iwCLL retweeted
Have you submitted your #iwCLL2021 abstract yet? Visit iwcll2021.org/abstracts/ for full list of guidelines, and to submit. Deadline is June 30th! Meeting registration is COMPLIMENTARY for all whose abstracts are accepted for oral/poster presentation. CC: @iwCLL #CLL #leukemia
iwCLL retweeted
Excited to see the official announcement @iwCLL #iwCLL2019 of the plans to open a very important new trial, CLL17, by the GCLLSG led by @Othman_Al_Sawaf and @HallekMichael. Great potential to help patients with CLL around the world!
iwCLL retweeted
Updated data from the clinical trial #E1912 FCR vs. Ibrutinib in #CLL naive pts. <70yo. @iwCLL #iwCLL2019
iwCLL retweeted
E1912 trial @iwCLL #iwCLL2019 pts who stopped ibrutinib for toxicity had a median PFS from the time of stopping ibrutinib of about 2 years. @anthonymatomd @tobyeyre82 @DrMDavids @sparikhmd @wwierda we all see this phenomenon in clinical practice, good to see data from a RCT – at Edinburgh, Scotland
iwCLL retweeted
Important and first major non-trial comparison of #venetoclax (+/-CD20mab) vs #ibrutinib vs #idelalsib as the first novel agent in #CLL. No clear difference in PFS and OS outcomes when comparing BCL2i and BTKi as first NA. #CLL #iwCLL2019 with @anthonymatomd
iwCLL retweeted
Prof. @AnnaSchuh3 Associate Professor In Haematology, University of Oxford reiterates the message that TP53 & FISH testing prior to any change in TX options is essential for #CLL patients
#iwCLL2019 #CLLHZ19
